Not all people with CLL involve therapy. Inspite of all the latest developments, the iwCLL even now endorses watchful observation for patients with asymptomatic condition.86 This suggestion is predicated on at least two randomized trials comparing observation to both chlorambucil monotherapy or fludarabine, cyclophosphamide and rituximab (FCR).103,